Purpose: We investigated the association of age, sex, race, and insurance status on antipsychotic medication use among intensive care unit (ICU) patients.

Materials And Methods: Retrospective study of adults admitted to ICUs at a tertiary academic center. Patient characteristics, hospital course, and medication (olanzapine, quetiapine, and haloperidol) data were collected. Logistic regression models evaluated the independent association of age, sex, race, and insurance status on the use of each antipsychotic, adjusting for prespecified covariates.

Results: Of 27,137 encounters identified, 6191 (22.8%) received antipsychotics. Age was significantly associated with the odds of receiving olanzapine ( < .001), quetiapine ( = .001), and haloperidol ( = .0046). Male sex and public insurance status were associated with increased odds of receiving antipsychotics olanzapine, quetiapine, and haloperidol (Male vs Female: OR 1.13, 95% CI [1.04, 1.24],  = .0005; OR 1.22, 95% CI [1.10, 1.34],  = .0001; OR 1.28, 95% CI [1.17, 1.40],  < .0001, respectively; public insurance vs private insurance: OR 1.32, 95% CI [1.20, 1.46],  < .0001; OR 1.21, 95% CI [1.09, 1.34],  = .0004; OR 1.15, 95% CI [1.04, 1.27],  = .0058, respectively). Black race was also associated with a decreased odds of receiving all antipsychotics (olanzapine ( = .0177), quetiapine ( = .004), haloperidol ( = .0041)).

Conclusions: Age, sex, race, and insurance status were associated with the use of all antipsychotic medications investigated, highlighting the importance of investigating the potential impact of these prescribing decisions on patient outcomes across diverse populations. Recognizing how nonmodifiable patient factors have the potential to influence prescribing practices may be considered an important factor toward optimizing medication regimens.

Download full-text PDF

Source
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC10771026PMC
http://dx.doi.org/10.1177/08850666231198030DOI Listing

Publication Analysis

Top Keywords

antipsychotic medication
8
medication intensive
8
intensive care
8
care unit
8
association age
8
age sex
8
sex race
8
race insurance
8
insurance status
8
status antipsychotic
8

Similar Publications

Psychotropic Taxonomies: Constructing a Therapeutic Framework for Psychiatry.

Biol Psychiatry

December 2024

Department of Psychosis Studies, Institute of Psychiatry, Psychology and Neuroscience, King's College London, London, UK; South London and Maudsley NHS Foundation Trust, London, UK.

Pharmacological interventions are a cornerstone of psychiatric practice. The taxonomies used to classify these interventions influence the treatment and interpretation of psychiatric symptoms. Disease-based classification systems (e.

View Article and Find Full Text PDF

Background: Symptom severity and social functioning are important outcomes after first episode psychosis (FEP), yet current evidence about associations between them is inconsistent and lacks (subclinical) momentary insights.

Methods: The current Ecological Momentary Assessment (EMA) study was conducted in 58 people in remission from FEP, as part of the HAMLETT (Handling Antipsychotic Medication: Long-term Evaluation of Targeted Treatment) trial. At baseline, participants were prompted to report momentary mental states and social context 10x/day for eight consecutive days, including psychotic experiences (PEs), motivation/drive and negative affect, that may indicate proxies of (subclinical) psychotic, negative and general affective symptoms, respectively.

View Article and Find Full Text PDF

Clozapine treatment continues to be recognized as the gold standard for managing treatment-resistant schizophrenia. Combining clozapine with other antipsychotics (i.e.

View Article and Find Full Text PDF

Introduction And Objectives: Clozapine is the antipsychotic medication with the greatest efficacy in treatment-resistant schizophrenia (TRS). Unfortunately, clozapine is ceased in approximately 0.2% to 8.

View Article and Find Full Text PDF

Involuntary medication treatment of schizophrenia in the inpatient setting.

Ment Health Clin

December 2024

 (Corresponding author) Clinical Manager and PGY-2 Residency Program Director, Department of Pharmacy, Center for Behavioral Medicine, Kansas City, Missouri,

Two Supreme Court cases in the United States describe the use of involuntary medication in individuals with mental illnesses. In addition to these legal requirements, clinicians must also incorporate ethics into treating these individuals, including the principles of autonomy and beneficence. Current guidelines do not provide specific recommendations for choosing an antipsychotic for a patient with schizophrenia who is being treated involuntarily.

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!